• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Allogene Therapeutics, Inc. - Common Stock (NQ:ALLO)

1.390 -0.040 (-2.80%)
Delayed Quote Updated: 9:43 AM EDT, Oct 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 191,980
Open 1.440
Bid (Size) 1.390 (3,000)
Ask (Size) 1.400 (5,700)
Prev. Close 1.430
Today's Range 1.390 - 1.440
52wk Range 1.040 - 4.460
Shares Outstanding 142,183,418
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker
September 02, 2026
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Announces Participation in September Investor Conference
August 31, 2026
From Allogene Therapeutics, Inc.
Via GlobeNewswire

Performance

52-Week Range 68.8% below 52-week high
1.390
1.0452W Low 4.4652W High
1 Week 13.7% below 1-week high
1.421W Low 1.611W High

Allogene Therapeutics, Inc. - Common Stock (ALLO) traded between $1.04 and $4.46 over the past 52 weeks and last traded at $1.39, 68.8% below its 52-week high. Over the past week it ranged between $1.42 and $1.61.

Past 12 Months
-9.7%
-25.3%
-34.4%
-48.5%
+3.0%
+3.0%
1W -$0.15
1M -$0.47
3M -$0.73
6M -$1.31
YTD +$0.04
1Y +$0.04

ALLO was +3.0% over the past year, -48.5% over six months, +3.0% year to date, -9.7% in the last week.

12 Months vs Market
ALLO
+3.0%
DIA
+9.5%
SPY
+15.8%
QQQ
+24.6%
IWM
+13.0%

Over the past 12 months ALLO returned +3.0% versus DIA (Dow) +9.5%, SPY (S&P 500) +15.8%, QQQ (Nasdaq 100) +24.6% and IWM (Russell 2000) +13.0%.

Volume & Liquidity 0.03× 3-mo avg
Today 191,980 3-mo avg 5.7M
1W
4.5M
1M
5.7M
3M
5.7M
6M
8.6M
YTD
7.7M
1Y
6.5M

ALLO most recently traded 191,980 shares against a 3-month average daily volume of 5.7M.

More News

Read More
News headline image
Allogene (ALLO) Q2 2026 Earnings Call Transcript ↗
August 19, 2026
Via The Motley Fool
Topics Earnings
News headline image
Allogene Therapeutics Q2 Earnings Call Highlights ↗
August 12, 2026
Via MarketBeat
Topics Earnings
News headline image
Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update
August 12, 2026
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update
August 04, 2026
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma
July 29, 2026
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors
July 15, 2026
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Announces Planned CEO Succession
May 28, 2026
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
May 26, 2026
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Q1 Earnings Call Highlights ↗
May 13, 2026
Via MarketBeat
Topics Earnings
News headline image
Allogene (ALLO) Q1 2026 Earnings Transcript ↗
May 13, 2026
Via The Motley Fool
News headline image
Allogene Therapeutics Q1 2026 Earnings Call Transcript ↗
May 13, 2026
Via Benzinga
Topics Earnings
News headline image
Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update
May 13, 2026
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
May 06, 2026
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia
April 21, 2026
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026
April 20, 2026
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock
April 16, 2026
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Thursday's session: gap up and gap down stocks ↗
April 16, 2026
Via Chartmill
News headline image
Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases
April 15, 2026
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Announces Pricing of Public Offering of Common Stock
April 14, 2026
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
JPMorgan, Allogene Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
April 14, 2026
Via Benzinga
News headline image
Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock
April 13, 2026
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
These stocks are making the most noise in today's session. ↗
April 13, 2026
Via Chartmill
News headline image
ENDRA Life Sciences (NASDAQ: NDRA) Targets Billions With TAEUS® Liver Imaging Technology
April 13, 2026
Via AB Newswire

Frequently Asked Questions

Is Allogene Therapeutics, Inc. - Common Stock publicly traded?
Yes, Allogene Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Allogene Therapeutics, Inc. - Common Stock trade on?
Allogene Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Allogene Therapeutics, Inc. - Common Stock?
The ticker symbol for Allogene Therapeutics, Inc. - Common Stock is ALLO on the Nasdaq Stock Market
What is the current price of Allogene Therapeutics, Inc. - Common Stock?
The current price of Allogene Therapeutics, Inc. - Common Stock is 1.390
When was Allogene Therapeutics, Inc. - Common Stock last traded?
The last trade of Allogene Therapeutics, Inc. - Common Stock was at 10/08/26 09:43 AM ET
What is the market capitalization of Allogene Therapeutics, Inc. - Common Stock?
The market capitalization of Allogene Therapeutics, Inc. - Common Stock is 197.63M
How many shares of Allogene Therapeutics, Inc. - Common Stock are outstanding?
Allogene Therapeutics, Inc. - Common Stock has 198M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap